PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29463558-5	2018	We investigated the antileukemia activity of combined Wnt/beta-catenin and FLT3 inhibition in FLT3-mutant AML.Experimental Design: Wnt/beta-catenin signaling was inhibited by the beta-catenin/CBP antagonist C-82/PRI-724 or siRNAs, and FLT3 signaling by sorafenib or quizartinib.	quizartinib	266-277	catenin beta 1	Homo sapiens	135-147	
29463558-5	2018	We investigated the antileukemia activity of combined Wnt/beta-catenin and FLT3 inhibition in FLT3-mutant AML.Experimental Design: Wnt/beta-catenin signaling was inhibited by the beta-catenin/CBP antagonist C-82/PRI-724 or siRNAs, and FLT3 signaling by sorafenib or quizartinib.	quizartinib	266-277	catenin beta 1	Homo sapiens	135-147